Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Two Infants.
- Resource Type
- Article
- Authors
- Gallagher, Joel; Patel, Niraj
- Source
- Journal of Clinical Immunology. Jun2012, Vol. 32 Issue 3, p474-476. 3p.
- Subject
- *IMMUNOGLOBULINS
*SUBCUTANEOUS surgery
*TREATMENT effectiveness
*IMMUNOGLOBULIN G
*IMMUNODEFICIENCY
*INFANT disease treatment
- Language
- ISSN
- 0271-9142
Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective. [ABSTRACT FROM AUTHOR]